Sclerostin and dickkopf-1 (DKK1) played a role in the introduction of cardiovascular illnesses and arterial rigidity in chronic kidney disease (CKD) sufferers but with controversial outcomes of sufferers in end-stage renal disease (ESRD) including hemodialysis (HD) and peritoneal dialysis (PD). had been 21 (29.2%) of PD and 53 (43.4%) of HD in the high AS group. In comparison to sufferers in the control group, those in the high AS group had been older, had even more comorbidities, got higher systolic blood circulation pressure, and got higher serum degrees of fasting glucose, C-reactive protein, and sclerostin. Levels of sclerostin (adjusted OR 1.012, 95% CI. 1.006C1.017, = 0.0001) was found to be an independent predictor of high AS in ESRD patients by multivariate logistic regression analysis. Furthermore, receiver operating Roscovitine manufacturer characteristic curve analysis showed the optimal cut-off values of sclerostin for predicting AS was 208.64 pmol/L (Area under the curve Rabbit polyclonal to Dopey 2 0.673, 95% CI: 0.603C0.739, 0.001). This study showed that serum levels of sclerostin, but not DKK1 or mode of dialysis, to be a predictor for high central AS in ESRD patients. = 194)= 120)= 74)(%)101 (52.1)69 (57.5)32 (43.2)0.075Dialysis duration (mo)48.5 (22C96)42.5 (18.5C96.5)57 (28C90)0.077BMI (Kg/m2)24.91 4.8224.58 4.8325.45 4.800.226SBP (mmHg)142.29 24.94138.09 25.54149.11 22.460.003 *DBP (mmHg)79.66 15.7478.81 14.8481.05 17.120.336cfPWV (m/s)9.0 (7.5C11.7)7.7 (7.0C8.9)12.3 (11.4C14.3) 0.001 *BUN (mg/dL)60 (50C70)60.0 (49.5C67.5)61.0 (50.0C71.0)0.564Creatinine (mg/dL)9.91 2.679.90 2.839.95 2.430.901Calcium (mg/dL)9.02 0.768.96 0.719.11 0.840.197IP (mg/dL)4.92 1.344.94 1.374.90 1.290.842Albumin (mg/dL)4.06 (3.7C4.2)4.01 (3.70C4.30)4.10 (3.70C4.20)0.644TCH (mg/dL)154.73 39.13157.55 40.58150.15 36.470.202TG (mg/dL)125 (87C197)114.0 (87.5C199.0)133.0 (87.0C189.0)0.473Glucose Roscovitine manufacturer (mg/dL)120 (100C149)114.5 (97.0C142.0)131.0 (110.0C182.0)0.001CRP (mg/dL)0.32 (0.09C0.90)0.195 (0.06C0.780)0.465 (0.25C1.05)0.0001 *iPTH (pg/mL)230.15 (89.91C486.30)252.15 (123.07C503.86)167.25 (73.01C434.10)0.111Sclerostin (pmol/L)143.50 (97.21C191.7)132.09 (89.58C175.44)157.41 (129.45C236.33)0.0001 *DKK-1 (pmol/L)12.08 (7.15C19.93)11.96 (7.25C19.15)12.86 (6.90C24.96)0.563Mode, n (%) 0.001PD72 (37.1)51 (70.8)21 Roscovitine manufacturer (29.2) HD122 (62.9)69 (56.6)53 (43.4) Cormobidity n (%) 0.003No48 (24.7)37 (30.8)11 (14.9) Diabetes mellitus64 (33.0)44 (36.7)20 (27.0) Hypertension25 (12.9)14 (11.7)11 (14.9) Both57 (29.4)25 (20.8)32 (43.2) ARB, (%)66 (34.0)43 (35.8)27 (36.5)0.951-blocker, (%)63 (32.5)38 (31.7)25 (33.8)0.882CCB, (%)82 (42.3)55 (45.8)27 (36.5)0.258Statin, (%)40 (20.6)24 (20.0)16 (21.6)0.930 Open in a separate window BMI, body mass index. cfPWV, carotid-femoral pulse wave velocity. TCH, total cholesterol. TG, triglyceride. HD, hemodialysis. PD, peritoneal dialysis. SBP, systolic blood pressure. DBP, diastolic blood pressure. BUN, blood urea nitrogen. CRP, C-reactive protein. iPTH, intact parathyroid hormone. IP, inorganic phosphate. DKK-1, dickkopf-1. Kt/V, fractional clearance index for urea. ARB, angiotensin receptor blocker. CCB, calcium channel blocker. Continuous variables are shown as mean standard deviation or median and interquartile range after analysis by Students t-test or Mann-Whitney U test according to the analysis for normal distribution. Categorical variables are presented as number (%) and analyzed by a chi-square test. Mode of dialysis was analyzed by chi-squared with a continuity correction. * 0.05 was statistically significant. Roscovitine manufacturer Table 2 Clinical characteristics of the HD patients in high AS and control groups. = 122)= 69)= 53)(%)60 (49.2)37 (53.6)23 (43.4)0.263HD duration (mo)57.00 (25.53C119.34)58.20 (21.84C131.94)56.88 (26.70C104.82)0.857BMI (Kg/m2)24.92 5.0624.63 5.2825.29 4.780.479DM, (%)52 (42.6)19 (27.5)33 (62.3) 0.001 *HTN, (%)59 (48.4)27 (39.1)32 (60.4)0.020 *SBP (mmHg)142.47 25.61137.67 26.59148.72 23.050.018 *DBP (mmHg)76.74 16.4076.07 15.6377.60 17.460.611cfPWV (m/s)10.07 2.987.88 1.1712.92 2.06 0.001 *BUN (mg/dL)61.06 15.6160.77 14.9461.43 16.580.816Creatinine (mg/dL)9.32 2.079.36 2.089.28 2.090.836Calcium (mg/dL)9.00 0.748.94 0.719.07 0.790.331IP (mg/dL)4.76 1.264.75 1.254.79 1.290.862Albumin (mg/dL)4.17 0.464.18 0.474.16 0.450.840TCH (mg/dL)144.65 35.32147.45 39.38141.00 29.180.320TG (mg/dL)113.00 (85.50-187.00)106.00 (85.00C192.50)127.00 (85.00C184.00)0.437Glucose (mg/dL)130.50 (117.75C169.00)128.00 (106.50C153.50)137.00 (114.00C185.50)0.084CRP (mg/dL)0.41 (0.12C0.92)0.25 (0.08C0.79)0.59 (0.25C1.05)0.003 *iPTH (pg/mL)204.05 (84.08C416.65)244.40 (121.90C445.05)157.60 (58.00C392.15)0.180Sclerostin (pmol/L)133.54 (90.52C175.17)122.04 (83.74C163.63)144.49 (113.34C221.37)0.002 *DKK-1 (pmol/L)13.25 (7.40C22.61)12.74 (7.34C21.07)14.42 (7.69C26.70)0.586Urea reduction rate0.73 0.040.74 0.040.73 0.040.689Kt/V (Gotch)1.34 0.171.35 0.171.33 0.160.658ARB, (%)36 (29.5)18 (26.1)18 (34.6)0.344-blocker, (%)38 (31.1)19 (27.5)19 (35.8)0.326CCB, (%)47 (38.5)30 (43.5)17 (32.1)0.200Statin, (%)20 (16.4)9 (13.0)11 (20.8)0.254 Open in a separate window BMI, body mass index. cfPWV, carotid-femoral pulse wave velocity. TCH, total cholesterol. TG, triglyceride. HD, hemodialysis. SBP, systolic blood pressure. DBP, diastolic blood pressure. BUN, blood urea nitrogen. CRP, C-reactive protein. iPTH, intact parathyroid hormone. IP, inorganic phosphate. DKK-1, dickkopf-1. Kt/V, Roscovitine manufacturer fractional clearance index for urea. ARB, angiotensin receptor blocker. CCB, calcium channel blocker. DM, diabetes mellitus. HTN, hypertension. Continuous variables are shown as mean standard deviation or median and interquartile range after analysis by Students t-test or Mann-Whitney U test according to analysis for normal distribution. Categorical variables are presented as number (%) and analyzed by a chi-square test. * 0.05 was statistically significant. Table.